GLP-1 vs semaglutide vs Ozempic
Direct answer
What you need to know
Evidence strength: StrongThese are not three products — they are three levels of one thing. “GLP-1” is the drug class. “Semaglutide” is one molecule in that class. “Ozempic” is one brand name under which that molecule is sold, for one approved use. Asking which is better is like asking whether a car is better than a diesel engine.
Key takeaways
- Class: GLP-1 receptor agonist. Molecule: semaglutide, tirzepatide, orforglipron. Brand: Ozempic, Wegovy, Zepbound and the rest.
- The same molecule appears under two brand names when it is approved for two different uses.
- Tirzepatide is a different molecule from semaglutide, so that comparison is real.
- “Is Ozempic a GLP-1?” — yes. So is Wegovy, and they are the same molecule.
Important limitation: This page explains naming, not which product is right for anyone. Where the molecules genuinely differ, the trial results come from separate trials and are not a head-to-head comparison.
Next action: If you are trying to work out which product your prescription is, the brand name on the box maps to a molecule in the table below. What it costs is on the cheapest-routes comparison.
Primary sources: DailyMed, U.S. National Library of Medicine, U.S. Food & Drug Administration, National Institute of Diabetes and Digestive and Kidney Diseases (NIH)
General education, not medical advice.
The three levels, drawn
Ozempic and Wegovy are the same molecule. They differ in what they are approved to treat, and therefore in how insurers treat them — which is a real difference, just not a pharmacological one.
Which brand is which molecule
| Molecule | Sold as | Approved for | Form |
|---|---|---|---|
| semaglutide | Wegovy | chronic weight management | weekly injection or daily tablet |
| Ozempic | type 2 diabetes | weekly injection | |
| Rybelsus | type 2 diabetes | daily tablet | |
| tirzepatide | Zepbound | chronic weight management | weekly injection |
| Mounjaro | type 2 diabetes | weekly injection | |
| orforglipron | Foundayo | chronic weight management | daily tablet |
| dulaglutide | Trulicity | type 2 diabetes | weekly injection |
| liraglutide | Victoza | type 2 diabetes | daily injection |
| Saxenda | chronic weight management | daily injection | |
| exenatide | Byetta | type 2 diabetes | twice-daily injection |
So what is a real comparison?
Two things on that table genuinely differ, and they are worth separating from the naming confusion:
- Different molecules. Semaglutide and tirzepatide are not the same drug. Tirzepatide acts at a second receptor as well, which is why it is described as a dual agonist — see how these medications work. Orforglipron is different again: a non-peptide small molecule, which is why it is the one tablet with no food-timing window.
- Different approvals for the same molecule. Ozempic and Wegovy are both semaglutide. Ozempic is approved for type 2 diabetes and Wegovy for chronic weight management. That distinction decides whether an insurer covers it, which is usually the practical question hiding inside “which is better” — see cost and coverage.
The questions this answers
Most of the “versus” searches in this category resolve once the three levels are separated:
- Is Ozempic a GLP-1? Yes. It is semaglutide, which is a GLP-1 receptor agonist.
- Is Wegovy a GLP-1? Yes, and it is the same molecule as Ozempic.
- Is Zepbound a GLP-1? Yes — it is tirzepatide, which acts at the GLP-1 receptor and at the GIP receptor as well.
- GLP-1 vs semaglutide? Not a comparison. Semaglutide is one of the GLP-1s.
- GLP-1 vs tirzepatide? Same shape of answer: tirzepatide is in the class, and does one extra thing.
Sources
Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.
- FDA-approved prescribing information (drug labels)DailyMed, U.S. National Library of MedicineSupports: The approved indication and dosage form for each brand-name product named — the source for which brand carries which approval.
- Drug approvals, labeling and safety communicationsU.S. Food & Drug AdministrationSupports: Approval status and the brand/generic relationship, checkable in Drugs@FDA and the Orange Book.
- Diabetes, obesity and digestive-disease informationNational Institute of Diabetes and Digestive and Kidney Diseases (NIH)Supports: GLP-1 as a naturally occurring incretin hormone, and the basis for the drug class being named after it.
This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.